相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer
Stephen E. Gilbert et al.
BRITISH JOURNAL OF CANCER (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Peter C. Albertsen et al.
EUROPEAN UROLOGY (2014)
Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial
Liam Bourke et al.
EUROPEAN UROLOGY (2014)
Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists
Laurence Klotz et al.
EUROPEAN UROLOGY (2014)
Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)
John Deanfield et al.
HEART (2014)
Degarelix relieves hydronephrosis in a patient with prostate cancer: case study
Bruce Turner et al.
INTERNATIONAL JOURNAL OF UROLOGICAL NURSING (2013)
Testosterone: a metabolic hormone in health and disease
Daniel M. Kelly et al.
JOURNAL OF ENDOCRINOLOGY (2013)
Experience with degarelix in the treatment of prostate cancer
Neal D. Shore
THERAPEUTIC ADVANCES IN UROLOGY (2013)
Screening for prostate cancer
Dragan Ilic et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Management of erectile dysfunction in men treated with androgen deprivation therapy
James M. Wilson et al.
TRENDS IN UROLOGY & MENS HEALTH (2013)
Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis
Herta H. Chao et al.
BMC CANCER (2012)
Androgen deprivation and thromboembolic events in men with prostate cancer
Behfar Ehdaie et al.
CANCER (2012)
Gonadotropin-releasing hormone: An update review of the antagonists versus agonists
Hein Van Poppel et al.
INTERNATIONAL JOURNAL OF UROLOGY (2012)
Skeletal receptors for steroid-family regulating glycoprotein hormones A multilevel, integrated physiological control system
Harry C. Blair et al.
SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND BONE DISEASE (2011)
'Nurse: My back hurts!': case study review of Degarelix in metastatic prostate cancer
Bruce Turner et al.
INTERNATIONAL JOURNAL OF UROLOGICAL NURSING (2011)
A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
E. David Crawford et al.
JOURNAL OF UROLOGY (2011)
An update on the use of gonadotropinreleasing hormone antagonists in prostate cancer
Laurent Boccon-Gibod et al.
THERAPEUTIC ADVANCES IN UROLOGY (2011)
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H. Schroder et al.
BJU INTERNATIONAL (2010)
Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association Endorsed by the American Society for Radiation Oncology
Glenn N. Levine et al.
CIRCULATION (2010)
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Bertrand Tombal et al.
EUROPEAN UROLOGY (2010)
Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden
Mieke Van Hemelrijck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
SWITCHING FROM LEUPROLIDE TO DEGARELIX VS CONTINUOUS DEGARELIX TREATMENT - EFFECTS ON LONG-TERM PROSTATE-SPECIFIC ANTIGEN CONTROL
E. David Crawford et al.
JOURNAL OF UROLOGY (2010)
Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels.
Aurelian Radu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients
Guo-Wen Lin et al.
ASIAN JOURNAL OF ANDROLOGY (2009)
GnRH blockers: a changing paradigm in the management of prostate cancer
Lawrence Drudge-Coates
INTERNATIONAL JOURNAL OF UROLOGICAL NURSING (2009)
Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease-Induced Congestive Heart Failure or Myocardial Infarction
Akash Nanda et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis
Peter Libby
JOURNAL OF LIPID RESEARCH (2009)
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Philip J. Saylor et al.
JOURNAL OF UROLOGY (2009)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Cognitive effects of hormone therapy in men with prostate cancer
Christian J. Nelson et al.
CANCER (2008)
Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases
Gary G. Schwartz
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy
Bertrand Tombal et al.
EUROPEAN UROLOGY SUPPLEMENTS (2008)
Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase
David Robinson et al.
JOURNAL OF UROLOGY (2008)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
How good do current LHRH agonists LHRH agonists control testosterone? -: Can this be improved with Eligard® ?
B Tombal et al.
EUROPEAN UROLOGY SUPPLEMENTS (2005)
GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor γ-chain mRNA expression in healthy males
F Tanriverdi et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone?
B Tombal
EUROPEAN UROLOGY SUPPLEMENTS (2005)
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial
HJ Green et al.
BJU INTERNATIONAL (2002)
Is the flare phenomenon clinically significant?
GJ Bubley
UROLOGY (2001)
Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making
MG Oefelein et al.
UROLOGY (2000)
分享论文
